Initial phase 2 trial of a nicotinic agonist in schizophrenia (Q34766663)

4 August 2017

Initial phase 2 trial of a nicotinic agonist in schizophrenia (English)

1 reference

4 August 2017

phase II clinical trial

0 references

0 references

2

Ann Olincy

1 reference

4 August 2017

Robert Freedman

1

1 reference

4 August 2017

Robert W Buchanan

3

1 reference

4 August 2017

Josette G Harris

4

1 reference

4 August 2017

James M Gold

5

1 reference

4 August 2017

Lynn Johnson

6

1 reference

4 August 2017

Diana Allensworth

7

1 reference

4 August 2017

Alejandrina Guzman-Bonilla

8

1 reference

4 August 2017

Bettye Clement

9

1 reference

4 August 2017

M Patricia Ball

10

1 reference

4 August 2017

Jay Kutnick

11

1 reference

4 August 2017

Vicki Pender

12

1 reference

4 August 2017

Laura F Martin

13

1 reference

4 August 2017

Karen E Stevens

14

1 reference

4 August 2017

Brandie D Wagner

15

1 reference

4 August 2017

Gary O Zerbe

16

1 reference

4 August 2017

Ferenc Soti

17

1 reference

4 August 2017

William R Kem

18

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

American Journal of Psychiatry

4 August 2017

1 reference

4 August 2017

165

1 reference

4 August 2017

1040-1047

1 reference

4 August 2017

8

1 reference

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Effects of nicotine nasal spray on cognitive function in schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Effects of clozapine on smoking in chronic schizophrenic outpatients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Negative symptoms in schizophrenia. Definition and reliability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

A rating scale for extrapyramidal side effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Galantamine for the treatment of cognitive impairments in people with schizophrenia.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Effects of nicotine on cognitive deficits in schizophrenia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Nicotine effects on brain function and functional connectivity in schizophrenia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Nicotine improves delayed recognition in schizophrenic patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Small sample inference for fixed effects from restricted maximum likelihood.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3746983

The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls

26 October 2018

1 reference

12 December 2020

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity

1 reference

12 December 2020

Clozapine's effect on negative symptoms in treatment-refractory schizophrenics

1 reference

12 December 2020

Smoking and therapeutic response to clozapine in patients with schizophrenia

1 reference

12 December 2020

10.1176/APPI.AJP.2008.07071135

Identifiers

DOI

1 reference

4 August 2017

1 reference

4 August 2017

1 reference